Takeda’s Febuxostat Gets Advisory Committee Nod for Gout; Cardio Risk Remains A Concern
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee members reach near-unanimous agreement to approve febuxostat for gout, but urge FDA to require post-approval cardiovascular studies.
You may also be interested in...
Did Takeda Make The Right Decisions Throughout The Uloric Review?
When FDA first turned Uloric down for approval, the agency stipulated that the cardiovascular adverse event issue needed further evaluation "by providing further comparative controlled clinical safety data, or, possibly, through reanalyses of the current database." The agency's letter adds, "Should a differential signal of thromboembolic CV events remain upon the analysis of new data and/or reanalyses of existing data, we would strongly encourage you to consider proposing the use of lower doses of Uloric, rather than those proposed."
Takeda Uloric Cleared For Gout Indication
Labeling for the xanthine oxidase inhibitor includes a Warning on cardiovascular safety, a concern of FDA’s.
Takeda Uloric Cleared For Gout Indication
Labeling for the xanthine oxidase inhibitor includes a Warning on cardiovascular safety, a concern of FDA’s.